Side-by-side · Research reference
IpamorelinvsMOTS-c
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed21/57 cited
BAnimal-StrongReviewed16/68 cited
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
01Mechanism of Action
Parameter
Ipamorelin
MOTS-c
Primary target
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Pathway
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Downstream effect
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Feedback intact?
Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Origin
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Antibody development
Not reported in short-term studies
—
02Dosage Protocols
Parameter
Ipamorelin
MOTS-c
Standard dose
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
Frequency
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Lower / starter dose
100 mcg per dose
2.5–5 mg / week
Recommended due to limited human data.
Evidence basis
Phase 1 + clinical practiceRaun 1998Sigalos 2018
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Duration
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
4–12 weeks (experimental)
Optimal cycle length unknown.
Reconstitution
Bacteriostatic water; typical 2 mL per 5 mg vial
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Timing
Pre-sleep + fasted preferred; 30 min away from food
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Half-life
~2 hoursRaun 1998
Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
03Metabolic / Fat Loss Evidence
Parameter
Ipamorelin
MOTS-c
Primary fat target
—
Diet-induced / metabolic obesity; systemic fat utilization
Quantified reduction
—
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
IGF-1 impact
—
No direct IGF-1 pathway; AMPK-mediated
Effect on lean mass
—
High dose significantly ↑ lean mass in mice
Triglycerides
—
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
Effect reversibility
—
Unknown — no long-term follow-up data
Key publication
—
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
04Side Effects & Safety
Parameter
Ipamorelin
MOTS-c
Hunger
Mild appetite increase via ghrelin-receptor crosstalk
—
Injection site reaction
Mild irritation possible
Mild irritation (reported)
GH excess (overdose)
Joint pain, edema, insulin resistance
—
IGF-1 elevation
Dose-dependent; monitor with chronic high-dose use
—
Cancer risk
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
Contradictory data — some models suggest pro-proliferative effects
Pregnancy / OB
Avoid
Avoid — insufficient safety data
Fluid retention / Edema
—
Not reported
Cardiovascular
—
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
CNS / Neurological
—
Insomnia, headache (anecdotal reports)
GI symptoms
—
Nausea, stomach discomfort (reported)
Antibody formation
—
No data (no long-term human trials)
Evidence quality
—
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
Absolute Contraindications
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Relative Contraindications
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
05Administration Protocol
Parameter
Ipamorelin
MOTS-c
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
3. Timing
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
06Stack Synergy
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction